Cargando…

Neurotrophic factors and hippocampal activity in PTSD

Although numerous studies have investigated the neurotrophic factors and hippocampal activity in posttraumatic stress disorder (PTSD) separately each other, it is unclear whether an association between neurotrophic factors and hippocampal activity is present. The aim of this study was to evaluate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Tural, Ümit, Aker, Ahmet Tamer, Önder, Emin, Sodan, Hatice Turan, Ünver, Hatice, Akansel, Gür
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969740/
https://www.ncbi.nlm.nih.gov/pubmed/29799860
http://dx.doi.org/10.1371/journal.pone.0197889
_version_ 1783326006459760640
author Tural, Ümit
Aker, Ahmet Tamer
Önder, Emin
Sodan, Hatice Turan
Ünver, Hatice
Akansel, Gür
author_facet Tural, Ümit
Aker, Ahmet Tamer
Önder, Emin
Sodan, Hatice Turan
Ünver, Hatice
Akansel, Gür
author_sort Tural, Ümit
collection PubMed
description Although numerous studies have investigated the neurotrophic factors and hippocampal activity in posttraumatic stress disorder (PTSD) separately each other, it is unclear whether an association between neurotrophic factors and hippocampal activity is present. The aim of this study was to evaluate the functional changes in hippocampus before and after treatment with escitalopram and to associate these changes with peptides related to neuronal growth in patients with chronic PTSD and trauma survivors without PTSD. Fifteen earthquake survivors with chronic PTSD and thirteen drug naïve trauma exposed individuals without PTSD underwent fMRI scans in a block design. Serum levels of Nerve Growth Factor (NGF) and Brain Derived Neurotrophic Factor (BDNF) were measured before and after 12 weeks treatment with escitalopram. Baseline median serum level of NGF was significantly lower in patients with chronic PTSD than trauma survivors; however, 12 weeks of treatment with escitalopram significantly increased it. Higher activation was found both in left and right hippocampus for chronic PTSD group than trauma survivors. Treatment with escitalopram was significantly associated with suppression of the hyperactivation in left hippocampus in patients with chronic PTSD. Bilateral hyperactivation in hippocampus and lowered NGF may associate with neurobiological disarrangements in chronic PTSD. Treatment with escitalopram was significantly associated with both improvement in the severity of PTSD symptoms and biological alterations. Patients diagnosed with PTSD may have further and complicated deteriorations in hippocampal networks and neurotransmitter systems than individuals who had not been diagnosed with PTSD following the same traumatic experience.
format Online
Article
Text
id pubmed-5969740
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-59697402018-06-08 Neurotrophic factors and hippocampal activity in PTSD Tural, Ümit Aker, Ahmet Tamer Önder, Emin Sodan, Hatice Turan Ünver, Hatice Akansel, Gür PLoS One Research Article Although numerous studies have investigated the neurotrophic factors and hippocampal activity in posttraumatic stress disorder (PTSD) separately each other, it is unclear whether an association between neurotrophic factors and hippocampal activity is present. The aim of this study was to evaluate the functional changes in hippocampus before and after treatment with escitalopram and to associate these changes with peptides related to neuronal growth in patients with chronic PTSD and trauma survivors without PTSD. Fifteen earthquake survivors with chronic PTSD and thirteen drug naïve trauma exposed individuals without PTSD underwent fMRI scans in a block design. Serum levels of Nerve Growth Factor (NGF) and Brain Derived Neurotrophic Factor (BDNF) were measured before and after 12 weeks treatment with escitalopram. Baseline median serum level of NGF was significantly lower in patients with chronic PTSD than trauma survivors; however, 12 weeks of treatment with escitalopram significantly increased it. Higher activation was found both in left and right hippocampus for chronic PTSD group than trauma survivors. Treatment with escitalopram was significantly associated with suppression of the hyperactivation in left hippocampus in patients with chronic PTSD. Bilateral hyperactivation in hippocampus and lowered NGF may associate with neurobiological disarrangements in chronic PTSD. Treatment with escitalopram was significantly associated with both improvement in the severity of PTSD symptoms and biological alterations. Patients diagnosed with PTSD may have further and complicated deteriorations in hippocampal networks and neurotransmitter systems than individuals who had not been diagnosed with PTSD following the same traumatic experience. Public Library of Science 2018-05-25 /pmc/articles/PMC5969740/ /pubmed/29799860 http://dx.doi.org/10.1371/journal.pone.0197889 Text en © 2018 Tural et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Tural, Ümit
Aker, Ahmet Tamer
Önder, Emin
Sodan, Hatice Turan
Ünver, Hatice
Akansel, Gür
Neurotrophic factors and hippocampal activity in PTSD
title Neurotrophic factors and hippocampal activity in PTSD
title_full Neurotrophic factors and hippocampal activity in PTSD
title_fullStr Neurotrophic factors and hippocampal activity in PTSD
title_full_unstemmed Neurotrophic factors and hippocampal activity in PTSD
title_short Neurotrophic factors and hippocampal activity in PTSD
title_sort neurotrophic factors and hippocampal activity in ptsd
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969740/
https://www.ncbi.nlm.nih.gov/pubmed/29799860
http://dx.doi.org/10.1371/journal.pone.0197889
work_keys_str_mv AT turalumit neurotrophicfactorsandhippocampalactivityinptsd
AT akerahmettamer neurotrophicfactorsandhippocampalactivityinptsd
AT onderemin neurotrophicfactorsandhippocampalactivityinptsd
AT sodanhaticeturan neurotrophicfactorsandhippocampalactivityinptsd
AT unverhatice neurotrophicfactorsandhippocampalactivityinptsd
AT akanselgur neurotrophicfactorsandhippocampalactivityinptsd